Medcentral: Head-to-Head Trials Highlight Efficacy Hierarchies in Psoriasis Therapies

Dr. Rachel Day, board-certified dermatologist specializing in eczema and psoriasis and Chief Medical Officer at Zest Health, was interviewed by MedCentral on a systematic review that compared the safety and efficacy of biologics and small molecule therapies for moderate-to-severe psoriasis. 

The evidence shared in the review shows that newer biologics are leading the way in both speed and durability of response for psoriasis treatments.

Dr. Day commented on the findings, emphasizing the clinicians safe and highly effective treatments clinicians have access to to treat their patients with moderate-to-severe psoriasis. 

She says the review includes clear, evidence-based comparisons for clinicians to make the most informed decisions for their patients but more data is still needed given the impact that cost has on treatment access.